Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study

Mu, Yun; Dickens, Borame Sue Lee; Yoong, Joanne; Chen, Mark; Teerawattananon, Yot; Cook, Alex R.

doi:10.1016/j.jval.2019.07.001

Cited by 15 publications

(30 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly this reduction of the trend in influenza could reflect higher Covid-19 mortality results. Also, in these three countries, the influenza mortality (2.8, 1.7, and 2.3/100,000 respectively) and hospitalization rates (37,36, and 30/100,000 respectively) are comparable to or less than those in Highincome North America and Western Europe reflecting a reducing influenza burden. New Zealand also has a similar trend with the influenza samples.…”

Section: Influenza Burdenmentioning

confidence: 84%

See 1 more Smart Citation

Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality—Perspectives

Arokiaraj

2020

Front. Public Health

View full text Add to dashboard Cite

Aims and objectives: The pandemic of COVID-19 is evolving worldwide, and it is associated with high mortality and morbidity. There is a growing need to discuss the elements of a coordinated strategy to control the spread and mitigate the severity of COVID-19. H1N1 and Streptococcus pneumonia vaccines are available. The current analysis was performed to analyze the severity of COVID-19 and influenza (H1N1) vaccination in adults ≥ 65. Also, to correlate the lower respiratory tract infections (LRIs), and influenza attributable to the lower respiratory tract infections' incidence with Covid-19 mortality. Evolutionarily influenza is close in resemblance to SARS-CoV-2 viruses and shares some common epitopes and mechanisms. Methods: Recent influenza vaccination data of 34 countries from OECD and other publications were correlated with COVID-19 mortality from worldometer data. LRIs attributable to influenza and streptococcus pneumonia were correlated with COVID-19 mortality. Specifically, influenza-attributable LRI incidence data of various countries (n = 182) was correlated with COVID-19 death by linear regression and receiver operating characteristic (ROC) curve analyzes. In a logistic regression model, population density and influenza LRI incidence were correlated with COVID-19 mortality. Results: There is a correlation between COVID-19-related mortality, morbidity, and case incidence and the status of influenza vaccination, which appears protective. The tendency of correlation is increasingly highlighted as the pandemic is evolving. In countries where influenza immunization is less common, there is a correlation between LRIs and influenza attributable to LRI incidence and COVID-19 severity, which is beneficial. ROC curve showed an area under the curve of 0.86 (CI 0.78 to 0.944, P < 0.0001) to predict COVID-19 mortality >150/million and a decreasing trend of influenza LRI episodes. To predict COVID-19 mortality of >200/million population, the odds ratio for influenza incidence/100,000 was −1.86 (CI −2.75 to −0.96, P < 0.0001). To predict the parameter Covid-19 mortality/influenza LRI episodes * 1000>1000, the influenza parameter had an odd's ratio of −3.83 (CI −5.98 to −1.67), and an AUC of 0.94. Arokiaraj Influenza Reduces COVID-19 Severity Conclusion: Influenza (H1N1) vaccination can be used as an interim measure to mitigate the severity of COVID-19 in the general population. In appropriate highrisk circumstances, Streptococcus pneumonia vaccination would also be an adjunct strategy, especially in countries with a lower incidence of LRIs.

show abstract

Section: Influenza Burdenmentioning

confidence: 84%

“…The average cost for H1N1 vaccination is about 30 US dollars. If a Streptococcus pneumonia vaccination is included, the total cost of vaccination would be ∼60 US dollars or less per person (36). A comparison of this expenditure could be the cost of a few days' worth of face masks used by these individuals.…”

Section: Cost and Strategymentioning

confidence: 99%

Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality—Perspectives

Arokiaraj

2020

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Over 65 years: In 23 of 25 studies, vaccination was considered cost-effective [ 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 ]. The studies were carried out with economic models in 20 countries (including eight countries in the Americas) and analyzed vaccination with trivalent vaccine, or CE of the use of high-dose trivalent, with adjuvants, or quadrivalent.…”

Section: Resultsmentioning

confidence: 99%

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Liprandi

Zaidel

et al. 2021

Global Heart

View full text Add to dashboard Cite

Background: Cardiovascular mortality is decreasing but remains the leading cause of death world-wide. Respiratory infections such as influenza significantly contribute to morbidity and mortality in patients with cardiovascular disease. Despite of proven benefits, influenza vaccination is not fully implemented, especially in Latin America. Objective: The aim was to develop a regional consensus with recommendations regarding influenza vaccination and cardiovascular disease. Methods: A multidisciplinary team composed by experts in the management and prevention of cardiovascular disease from the Americas, convened by the Inter-American Society of Cardiology (IASC) and the World Heart Federation (WHF), participated in the process and the formulation of statements. The modified RAND/UCLA methodology was used. This document was supported by a grant from the WHF. Results: An extensive literature search was divided into seven questions, and a total of 23 conclusions and 29 recommendations were achieved. There was no disagreement among experts in the conclusions or recommendations. Conclusions: There is a strong correlation between influenza and cardiovascular events. Influenza vaccination is not only safe and a proven strategy to reduce cardiovascular events, but it is also cost saving. We found several barriers for its global implementation and potential strategies to overcome them.

show abstract

“…10 Imperial College London, London, UK. 11 Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA.…”

Section: Acknowledgementsmentioning

confidence: 99%

“…There are no published influenza vaccine cost-effectiveness studies in Kenya. In other tropical settings with year-round influenza transmission, there is some quantification of the effect of elderly vaccination [11], but no evidence of the impact of vaccinating children.…”

Section: Introductionmentioning

confidence: 99%

Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling

Dawa

Emukule

Barasa

et al. 2020

BMC Med

View full text Add to dashboard Cite

Background: There is substantial burden of seasonal influenza in Kenya, which led the government to consider introducing a national influenza vaccination programme. Given the cost implications of a nationwide programme, local economic evaluation data are needed to inform policy on the design and benefits of influenza vaccination. We set out to estimate the cost-effectiveness of seasonal influenza vaccination in Kenya. Methods: We fitted an age-stratified dynamic transmission model to active surveillance data from patients with influenza from 2010 to 2018. Using a societal perspective, we developed a decision tree cost-effectiveness model and estimated the incremental cost-effectiveness ratio (ICER) per disability-adjusted life year (DALY) averted for three vaccine target groups: children 6-23 months (strategy I), 2-5 years (strategy II) and 6-14 years (strategy III) with either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or both (Strategy C: twice yearly vaccination campaigns, or Strategy D: year-round vaccination campaigns). We assessed cost-effectiveness by calculating incremental net monetary benefits (INMB) using a willingness-to-pay (WTP) threshold of 1-51% of the annual gross domestic product per capita ($17-$872). Results: The mean number of infections across all ages was 2-15 million per year. When vaccination was well timed to influenza activity, the annual mean ICER per DALY averted for vaccinating children 6-23 months ranged between $749

show abstract

Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study

Cited by 15 publications

References 41 publications

Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality—Perspectives

Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality—Perspectives

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling

Contact Info

Product

Resources

About